Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy

Liu,Yongping; Ling,Yang; Qi,Qiufeng; Lan,Feng; Zhu,Ming; Zhang,Yaping; Bao,Yanqing; Zhang,Changsong

doi:10.3892/mco.2017.1125

Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy

Authors:
- Yongping Liu
- Yang Ling
- Qiufeng Qi
- Feng Lan
- Ming Zhu
- Yaping Zhang
- Yanqing Bao
- Changsong Zhang
View Affiliations

Affiliations: Clinical Oncology Laboratory, Changzhou Tumor Hospital Affiliated to Suzhou University, Changzhou, Jiangsu 213002, P.R. China
Published online on: January 3, 2017 https://doi.org/10.3892/mco.2017.1125
Pages: 235-242

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The identification of circulating tumor cells (CTCs) may provide important prognostic information in several types of solid tumors, including gastric cancer. The aim of this study was to investigate whether CTC count may be used to predict survival in patients with advanced gastric cancer treated with chemotherapy. The CELLection™ Epithelial Enrich kit was used to isolate and purify CTCs from samples of peripheral blood. immunofluorescent staining was used for CTC counting. High CTC counts were associated with poor tumor differentiation and high serum CEA levels (P=0.021 and 0.005, respectively). After 3 months, 16 patients with decreasing CTC counts after the first cycle of chemotherapy obtained complete response, partial response or stable disease, while 13 patients with increasing CTC counts developed progressive disease. The patients with decreasing CTC counts also exhibited longer progression‑free survival (PFS) (P≤0.001) and overall survival (OS) (P=0.002) compared with those with increasing CTC counts. Among all 59 patients, those with a CTC count of ≤2 cells̸5 ml blood exhibited longer PFS (P≤0.001) and OS (P≤0.001) compared with those with a CTC count of >2 cells̸5 ml blood. The multivariate analysis suggested that an increase of the CTC count after the first cycle of chemotherapy was only an independent prognostic marker of poor PFS (P=0.019). However, a baseline CTC count of >2 cells̸5 ml blood was an independent poor prognostic marker for PFS (P=0.008) and OS (P=0.001) in all 59 patients. Our study suggested that patients with a low baseline CTC count or decrease of the CTC count after the first cycle of chemotherapy may benefit significantly from palliative chemotherapy. In conclusion, CTC count may be a good chemotherapy monitoring marker and an ideal prognostic marker for patients receiving palliative chemotherapy.

View Figures

View References

1	Lordick F, Lorenzen S, Yamada Y and Ilson D: Optimal chemotherapy for advanced gastric cancer: Is there a global consensus? Gastric Cancer. 17:213–225. 2014. View Article : Google Scholar : PubMed/NCBI
2	Methy N, Bedenne L and Bonnetain F: Surrogate endpoints for overall survival in digestive oncology trials: Which candidates? A questionnaires survey among clinicians and methodologists. BMC cancer. 10:2772010. View Article : Google Scholar : PubMed/NCBI
3	Shanbhogue AK, Karnad AB and Prasad SR: Tumor response evaluation in oncology: Current update. J Comput Assist Tomogr. 34:479–484. 2010. View Article : Google Scholar : PubMed/NCBI
4	Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M and Weitz J: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 138:1714–1726. 2010. View Article : Google Scholar : PubMed/NCBI
5	Thalgott M, Rack B, Eiber M, Souvatzoglou M, Heck MM, Kronester C, Andergassen U, Kehl V, Krause BJ, Gschwend JE, et al: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients. BMC cancer. 15:4582015. View Article : Google Scholar : PubMed/NCBI
6	Okabe H, Tsunoda S, Hosogi H, Hisamori S, Tanaka E, Tanaka S and Sakai Y: Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 22:3954–3961. 2015. View Article : Google Scholar : PubMed/NCBI
7	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lu Y, Liang H, Yu T, Xie J, Chen S, Dong H, Sinko PJ, Lian S, Xu J, Wang J, et al: Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer. 121:3036–3045. 2015. View Article : Google Scholar : PubMed/NCBI
9	Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM and Alpaugh RK: Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch^® CTC test. Cytometry A. 87:137–144. 2015. View Article : Google Scholar : PubMed/NCBI
10	Yu M, Stott S, Toner M, Maheswaran S and Haber DA: Circulating tumor cells: Approaches to isolation and characterization. J Cell Biol. 192:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
11	Gazzaniga P, Raimondi C, Nicolazzo C, Carletti R, di Gioia C, Gradilone A and Cortesi E: The rationale for liquid biopsy in colorectal cancer: A focus on circulating tumor cells. Expert Rev Mol Diagn. 15:925–932. 2015. View Article : Google Scholar : PubMed/NCBI
12	Antolovic D, Galindo L, Carstens A, Rahbari N, Büchler MW, Weitz J and Koch M: Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol. 10:352010. View Article : Google Scholar : PubMed/NCBI
13	Heo CK, Hwang HM, Ruem A, Yu DY, Lee JY, Yoo JS, Kim IG, Yoo HS, Oh S, Ko JH and Cho EW: Identification of a mimotope for circulating anti-cytokeratin 8/18 antibody and its usage for the diagnosis of breast cancer. Int J Oncol. 42:65–74. 2013.PubMed/NCBI
14	Wang Y, Zhu JF, Liu YY and Han GP: An analysis of cyclin D1, cytokeratin 5/6 and cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol. 8:82013. View Article : Google Scholar : PubMed/NCBI
15	Strassen U, Hofauer B, Matsuba Y, Becker K, Mansour N and Knopf A: Bronchogenic cancer: It still exists. Laryngoscope. 2015.
16	Yin J, Wang Y, Yin H, Chen W, Jin G, Ma H, Dai J, Chen J, Jiang Y, Wang H, et al: Circulating tumor cells enriched by the depletion of leukocytes with bi-antibodies in non-small cell lung cancer: Potential clinical application. PLoS One. 10:e01370762015. View Article : Google Scholar : PubMed/NCBI
17	Vaiopoulos AG, Kostakis ID, Gkioka E, Athanasoula KCh, Pikoulis E, Papalambros A, Christopoulos P, Gogas H, Kouraklis G and Koutsilieris M: Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Res. 34:3083–3092. 2014.PubMed/NCBI
18	Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, et al: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 10:8152–8162. 2004. View Article : Google Scholar : PubMed/NCBI
19	Najjar F, Alammar M, Bachour M and Al-Massarani G: Circulating endothelial cells as a biomarker in non-small cell lung cancer patients: Correlation with clinical outcome. Int J Biol Markers. 29:e337–e344. 2014. View Article : Google Scholar : PubMed/NCBI
20	Huang X, Gao P, Sun J, Chen X, Song Y, Zhao J, Xu H and Wang Z: Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis. Int J Cancer. 136:21–33. 2015. View Article : Google Scholar : PubMed/NCBI
21	Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al: Relationship of circulating tumor cells to tumor response, progression-free survival and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008. View Article : Google Scholar : PubMed/NCBI
22	Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, et al: Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat. 122:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
23	Court CM, Ankeny JS, Hou S, Tseng HR and Tomlinson JS: Improving pancreatic cancer diagnosis using circulating tumor cells: Prospects for staging and single-cell analysis. Expert Rev Mol Diagn. 15:1491–1504. 2015. View Article : Google Scholar : PubMed/NCBI
24	Tang L, Zhao S, Liu W, Parchim NF, Huang J, Tang Y, Gan P and Zhong M: Diagnostic accuracy of circulating tumor cells detection in gastric cancer: Systematic review and meta-analysis. BMC Cancer. 13:3142013. View Article : Google Scholar : PubMed/NCBI
25	Cristofanilli M: Circulating tumor cells, disease progression and survival in metastatic breast cancer. Semin Oncol. 33:(Suppl 9). S9–S14. 2006. View Article : Google Scholar : PubMed/NCBI
26	de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
27	Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U, Jörke C, Rabenstein C, Untch M and Pachmann K: The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol. 18:1484–1492. 2007. View Article : Google Scholar : PubMed/NCBI
28	Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, et al: Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biol Ther. 16:709–713. 2015. View Article : Google Scholar : PubMed/NCBI
29	Matsushita D, Uenosono Y, Arigami T, Yanagita S, Nishizono Y, Hagihara T, Hirata M, Haraguchi N, Arima H, Kijima Y, et al: Clinical significance of circulating tumor cells in peripheral blood of patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 22:3674–3680. 2015. View Article : Google Scholar : PubMed/NCBI
30	Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Liu J, Xu H and Wang Z: Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: A meta-analysis. BMC Cancer. 14:9762014. View Article : Google Scholar : PubMed/NCBI
31	Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M and Stölzel U: Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 89:294–303. 2015. View Article : Google Scholar : PubMed/NCBI
32	Fei F, Du Y, Di G, Wu J and Shao Z: Are changes in circulating tumor cell (CTC) count associated with the response to neoadjuvant chemotherapy in local advanced breast cancer? A meta-analysis. Oncol Res Treat. 37:250–254. 2014. View Article : Google Scholar : PubMed/NCBI